ASCO 2022 Conference Coverage

 

ASCO 2022 Conference Coverage
G

ASCO 2022: A Phase II Study of Gem + Cis Chemo in MIBC With Bladder Preservation for Patients Whose Tumors Harbor Deleterious DNA Damage Response Gene Alterations (Alliance A031701)

By ASCO 2022 Conference Coverage FEATURING Gopa Iyer
By ASCO 2022 Conference Coverage FEATURING Gopa Iyer
123 views
June 8, 2022
0 Comments
Login to view comments. Click here to Login
GU
21:32
ASCO 2022 Conference Coverage

ASCO 2022 Bladder Cancer Highlights

Feat. G. Sonpavde
04:42
ASCO 2022 Conference Coverage

ASCO 2022 on Olaparib + Abiraterone as 1L Therapy for mCRPC: Pharmac…

Feat. A. Armstrong
06:04
ASCO 2022 Conference Coverage

ASCO 2022 on Safety & Clinical Activity of MEDI5752, a PD-1/CTLA…

Feat. L. Albiges
05:15
ASCO 2022 Conference Coverage

ASCO 2022 on the Clinical Outcomes & Safety of Enzalutamide + AD…

Feat. R. Szmulewitz
04:00
ASCO 2022 Conference Coverage

ASCO 2022 CHAARTED Trial: Eight-Year Survival Rates by Baseline Prog…

Feat. A. Tripathi
03:11
ASCO 2022 Conference Coverage

ASCO 2022 Defining "Platinum-Ineligible" Pts With Metastat…

Feat. S. Gupta
03:44
ASCO 2022 Conference Coverage

ASCO 2022 MAIN-CAV: Phase III Randomized Trial of Maintenance Caboza…

Feat. S. Gupta
20:21
ASCO 2022 Conference Coverage

ASCO 2022 Highlights From Educational Sessions and Updates in Bladde…

Feat. P. Grivas
30:41
ASCO 2022 Conference Coverage

ASCO 2022 Ga-PSMA-11 PET Baseline Imaging as a Prognostic Tool for C…

Feat. P. Kuo
01:22
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Real-World Treatment Patterns and Clinic…

Feat. G. Sonpavde
09:17
ASCO 2022 Conference Coverage

ASCO 2022 Real-World Treatment Patterns and Clinical Outcomes With 1…

Feat. G. Sonpavde
09:23
ASCO 2022 Conference Coverage

ASCO 2022 on Randomized Phase II Trial of Neoadjuvant ADT + Abirater…

Feat. D. Bastos
08:05
ASCO 2022 Conference Coverage

ASCO 2022: A Phase II Study of Gem + Cis Chemo in MIBC With Bladder …

Feat. G. Iyer
05:47
ASCO 2022 Conference Coverage

ASCO 2022 Maturation of Overall Survival in TIVO-3 With Long-Term Fo…

Feat. B. Rini